Doctor’s Passport

Find your next topic

Explore the current textbook

Available drafts · Clinical review pending
Membership
Educational draft · awaiting clinical reviewUse Rapid for revision, not patient-care decisions. Check current national and local guidance and the BNF or BNFC before acting.
Rapid

Biopsy, resection, radiotherapy and supportive care concepts

Essential points for quick revision.

Saved on this device
!
Acute deterioration before definitive tumour treatment

Falling consciousness, pupil change, rapidly worsening deficit, seizure without recovery, haemorrhage or obstructive hydrocephalus requires emergency stabilisation and neurosurgical assessment before a routine biopsy or radiotherapy plan.

Action: Stabilise airway, breathing and circulation, treat active seizure, obtain urgent imaging and contact neurosurgery; control life-threatening mass effect while preserving tissue and treatment options when safely possible.

Synopsis

Explain how a neuro-oncology multidisciplinary team selects tissue acquisition, maximal safe resection, radiotherapy and supportive care according to tumour biology, anatomy, function and patient goals.

  • Biopsy establishes histological and molecular diagnosis when resection is unsafe or inappropriate; resection can add decompression and cytoreduction but must remain maximal safe, not maximal at any neurological cost.
  • Treatment selection is an MDT decision integrating current WHO diagnosis, molecular markers, tumour location and extent, symptoms, performance, comorbidity, prior therapy, prognosis and informed patient priorities.
  • Radiotherapy may be focal, stereotactic, fractionated or whole-brain depending on entity and target; its potential local control is balanced against acute toxicity and late cognitive, vascular, endocrine, cranial-nerve and radionecrosis risks.

Key red flags

New decline in consciousness, pupil asymmetry, posturing, repeated vomiting or rapid focal progression indicates mass effect, haemorrhage or hydrocephalus.

New fever, wound leakage, meningism or systemic instability after biopsy or resection suggests infection or CSF leak and needs urgent assessment.

New or worsening focal deficit after surgery may reflect haemorrhage, infarction, oedema or seizure rather than an expected recovery course.

Progressive dysphagia, aspiration, immobility or cognitive loss demands early supportive and rehabilitation intervention alongside oncological care.

A radiological lesion near eloquent cortex, brainstem, optic pathways or major vessels requires function-preserving planning; “maximal” resection never means sacrificing foreseeable major function.

A patient whose disease, frailty or preferences make disease-directed treatment more burdensome than beneficial still needs active supportive and palliative care, not abandonment.

Postoperative deterioration

New deficit, seizure, reduced consciousness, severe headache or vomiting after cranial surgery needs prompt examination and imaging for haemorrhage, infarction, oedema, hydrocephalus or infection.

Investigation priorities

01
Standard and advanced MRI reviewFirst step

Define lesion extent, eloquent relationships, target volumes and areas most likely to yield diagnostic tissue.

Management branches

Tissue and local-control pathwayNew intrinsic brain tumour in an adult

MRI shows a new intrinsic lesion and the patient is stable enough for planned specialist treatment.

  1. Refer at radiological diagnosis to the neuro-oncology MDT, begin supportive and rehabilitation needs assessment alongside active treatment, and define the immediate goals, neurological baseline, performance, anatomy, differential and whether emergency pressure control is needed.
  2. Choose maximal safe resection when decompression, cytoreduction and adequate tissue justify the functional risk; choose biopsy when resection is unsafe or inappropriate, and reserve monitoring without tissue for carefully selected lesions with typical very-low-grade features.

Key medicines

Dexamethasone for symptomatic tumour oedemaDose is individualised to symptoms and source. Adult metastatic guidance considers 4–8 mg/day for mild mass-effect symptoms and higher doses such as 16 mg/day for severe symptoms, followed by the fastest clinically tolerated taper.Not routine for an asymptomatic scan. Monitor glucose, infection, psychiatric effects, sleep, proximal weakness and gastrointestinal risk; prolonged courses suppress the adrenal axis. Discuss before biopsy when primary CNS lymphoma is possible if the patient is stable.
Open full textbook Answer 2 questions
Sources and review status3 sources · checked 13 Sept 2026 · clinical review pending
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 13 Sept 2026; clinical approval remains outstanding.

Authoring stateRapid draftClinical stateAwaiting reviewJurisdictionUnited Kingdom